Neil Kramer, MD
Rheumatology · Summit, NJNPI 1306808746
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,563 of the $37,473 with a category attached, or 70.9%. GSK accounts for 66.9% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2021 at $17,150 and has fallen 93.4% since, to $1,129 in 2025.
Across 350 payments — averaging $107.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$25K
- AstraZeneca$6K
- E.r. Squibb & Sons, L.L.C.$2K
- Novartis$1K
- Amgen$977
- Johnson & Johnson$520
- plus $2K from 27 others
Across 43 payments — averaging $40,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1M
- E.r. Squibb & Sons, L.L.C.$609K
- AstraZeneca$67K
- Aurinia Pharma U.S., Inc.$31K
- Biogen$24K
- GSK$8K
- plus $2K from 1 others
What the payments were for
- Consulting fees$26,56371%
- Speaking & faculty fees$5,40014%
- Food & beverage$5,30214%
- Education$2091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $25,062 |
| AstraZeneca(2 entities) | 13 | $5,512 |
| E.r. Squibb & Sons, L.L.C. | 21 | $2,098 |
| Novartis | 57 | $1,035 |
| Amgen(2 entities) | 68 | $977 |
| Johnson & Johnson | 24 | $520 |
| AbbVie | 28 | $399 |
| Pfizer | 24 | $385 |
| UCB, Inc. | 18 | $289 |
| Fresenius Kabi USA, LLC | 13 | $217 |
| Boehringer Ingelheim | 9 | $139 |
| Sanofi | 6 | $103 |
| Sobi, Inc | 6 | $96 |
| Pacira Therapeutics, Inc. | 6 | $91 |
| Bioventus LLC | 2 | $59 |
| Radius Health, Inc. | 3 | $59 |
| Genentech USA, Inc. | 4 | $55 |
| Organon | 3 | $49 |
| Lilly USA, LLC | 3 | $46 |
| Biocon Biologics Inc | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Bristol Myers Squibb | 2 | $29 |
| Medexus Pharma, Inc. | 2 | $25 |
| Invivyd Inc | 1 | $19 |
| Sandoz | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,473 in reported general payments places this provider in the 85th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orencia ClickjectAbatacept | 29 | $262,172 |
| Enbrel SureclickEtanercept | 22 | $161,158 |
| OrenciaAbatacept | 20 | $120,804 |
| Humira(Cf) PenAdalimumab | 15 | $103,974 |
| EnbrelEtanercept | 14 | $98,830 |
| RinvoqUpadacitinib | 13 | $80,966 |
| OtezlaApremilast | 14 | $77,191 |
| Cimzia (2 Pack)Certolizumab Pegol | 14 | $77,044 |
| Xeljanz XrTofacitinib Citrate | 14 | $75,913 |
| XeljanzTofacitinib Citrate | 12 | $68,039 |
| Hydroxychloroquine Sulfate | 64 | $2,924 |
| MethotrexateMethotrexate Sodium | 65 | $1,952 |
| Colchicine | 14 | $983 |
| Gabapentin | 20 | $365 |
| Celecoxib | 11 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $977 | $176,02228 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $2,098 | $120,80420 claims |
| AbbVieRinvoq | $399 | $80,96613 claims |
| UCB, Inc.Cimzia (2 Pack) | $289 | $77,04414 claims |
| PfizerXeljanz | $385 | $68,03912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Summit
- Jeffrey GreenbergSummit$399K
- Elliot RosensteinSummit$101K
- Krissy ChoiSummit$10K
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.